Press "Enter" to skip to content

Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug to treat a form of ovarian cancer in previously untreated patients.

Original source:

Also Read:   Astrazeneca gets marketing authorisation to use anti-diabetes drug for kidney disease